Lassa virus reverse genetics

Luis Martínez-Sobrido, Slobodan Paessler, Juan Carlos de la Torre

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

The Old World (OW) arenavirus Lassa (LASV) is estimated to infect several hundred thousand people yearly in West Africa, resulting in high numbers of Lassa fever (LF), a viral hemorrhagic fever (HF) disease associated with high morbidity and mortality. To date, no licensed vaccines are available to LASV infections, and anti-LASV drug therapy is limited to an off-label use of ribavirin (Rib) that is only partially effective. The development of reverse genetics has provided investigators with a novel and powerful approach for the investigation of the molecular, cell biology, and pathogenesis of LASV. The use of cell-based LASV minigenome (MG) systems has allowed examining the cis- and trans-acting factors involved in genome replication and gene transcription and the identification of novel drugable LASV targets. Likewise, it is now feasible to rescue infectious recombinant (r)LASV entirely from cloned cDNAs containing predetermined mutations in their genomes to investigate virus-host interactions and mechanisms of pathogenesis, as well as to facilitate screens to identify antiviral drugs against LASV and the implementation of novel strategies to develop live-attenuated vaccines (LAV). In this chapter we will summarize the stateof- the-art experimental procedures for implementation of LASV reverse genetics. In addition, we will briefly discuss some significant translational research developments that have been made possible upon the development of LASV reverse genetics.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages185-204
Number of pages20
Volume1602
DOIs
StatePublished - 2017

Publication series

NameMethods in Molecular Biology
Volume1602
ISSN (Print)1064-3745

Fingerprint

Lassa virus
Reverse Genetics
Old World Arenaviruses
Lassa Fever
Viral Hemorrhagic Fevers
Genome
Off-Label Use
Attenuated Vaccines
Western Africa
Translational Medical Research
Trans-Activators
Ribavirin
Art
Antiviral Agents
Cell Biology
Molecular Biology
Vaccines
Complementary DNA
Research Personnel
Viruses

Keywords

  • Lassa virus minigenome assays
  • Lassa virus rescue systems
  • Lassa virus reverse genetics
  • Recombinant Lassa virus

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Martínez-Sobrido, L., Paessler, S., & de la Torre, J. C. (2017). Lassa virus reverse genetics. In Methods in Molecular Biology (Vol. 1602, pp. 185-204). (Methods in Molecular Biology; Vol. 1602). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-6964-7_13

Lassa virus reverse genetics. / Martínez-Sobrido, Luis; Paessler, Slobodan; de la Torre, Juan Carlos.

Methods in Molecular Biology. Vol. 1602 Humana Press Inc., 2017. p. 185-204 (Methods in Molecular Biology; Vol. 1602).

Research output: Chapter in Book/Report/Conference proceedingChapter

Martínez-Sobrido, L, Paessler, S & de la Torre, JC 2017, Lassa virus reverse genetics. in Methods in Molecular Biology. vol. 1602, Methods in Molecular Biology, vol. 1602, Humana Press Inc., pp. 185-204. https://doi.org/10.1007/978-1-4939-6964-7_13
Martínez-Sobrido L, Paessler S, de la Torre JC. Lassa virus reverse genetics. In Methods in Molecular Biology. Vol. 1602. Humana Press Inc. 2017. p. 185-204. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-6964-7_13
Martínez-Sobrido, Luis ; Paessler, Slobodan ; de la Torre, Juan Carlos. / Lassa virus reverse genetics. Methods in Molecular Biology. Vol. 1602 Humana Press Inc., 2017. pp. 185-204 (Methods in Molecular Biology).
@inbook{6dab0041a1fc47a0a2201927ccc30473,
title = "Lassa virus reverse genetics",
abstract = "The Old World (OW) arenavirus Lassa (LASV) is estimated to infect several hundred thousand people yearly in West Africa, resulting in high numbers of Lassa fever (LF), a viral hemorrhagic fever (HF) disease associated with high morbidity and mortality. To date, no licensed vaccines are available to LASV infections, and anti-LASV drug therapy is limited to an off-label use of ribavirin (Rib) that is only partially effective. The development of reverse genetics has provided investigators with a novel and powerful approach for the investigation of the molecular, cell biology, and pathogenesis of LASV. The use of cell-based LASV minigenome (MG) systems has allowed examining the cis- and trans-acting factors involved in genome replication and gene transcription and the identification of novel drugable LASV targets. Likewise, it is now feasible to rescue infectious recombinant (r)LASV entirely from cloned cDNAs containing predetermined mutations in their genomes to investigate virus-host interactions and mechanisms of pathogenesis, as well as to facilitate screens to identify antiviral drugs against LASV and the implementation of novel strategies to develop live-attenuated vaccines (LAV). In this chapter we will summarize the stateof- the-art experimental procedures for implementation of LASV reverse genetics. In addition, we will briefly discuss some significant translational research developments that have been made possible upon the development of LASV reverse genetics.",
keywords = "Lassa virus minigenome assays, Lassa virus rescue systems, Lassa virus reverse genetics, Recombinant Lassa virus",
author = "Luis Mart{\'i}nez-Sobrido and Slobodan Paessler and {de la Torre}, {Juan Carlos}",
year = "2017",
doi = "10.1007/978-1-4939-6964-7_13",
language = "English (US)",
volume = "1602",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "185--204",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Lassa virus reverse genetics

AU - Martínez-Sobrido, Luis

AU - Paessler, Slobodan

AU - de la Torre, Juan Carlos

PY - 2017

Y1 - 2017

N2 - The Old World (OW) arenavirus Lassa (LASV) is estimated to infect several hundred thousand people yearly in West Africa, resulting in high numbers of Lassa fever (LF), a viral hemorrhagic fever (HF) disease associated with high morbidity and mortality. To date, no licensed vaccines are available to LASV infections, and anti-LASV drug therapy is limited to an off-label use of ribavirin (Rib) that is only partially effective. The development of reverse genetics has provided investigators with a novel and powerful approach for the investigation of the molecular, cell biology, and pathogenesis of LASV. The use of cell-based LASV minigenome (MG) systems has allowed examining the cis- and trans-acting factors involved in genome replication and gene transcription and the identification of novel drugable LASV targets. Likewise, it is now feasible to rescue infectious recombinant (r)LASV entirely from cloned cDNAs containing predetermined mutations in their genomes to investigate virus-host interactions and mechanisms of pathogenesis, as well as to facilitate screens to identify antiviral drugs against LASV and the implementation of novel strategies to develop live-attenuated vaccines (LAV). In this chapter we will summarize the stateof- the-art experimental procedures for implementation of LASV reverse genetics. In addition, we will briefly discuss some significant translational research developments that have been made possible upon the development of LASV reverse genetics.

AB - The Old World (OW) arenavirus Lassa (LASV) is estimated to infect several hundred thousand people yearly in West Africa, resulting in high numbers of Lassa fever (LF), a viral hemorrhagic fever (HF) disease associated with high morbidity and mortality. To date, no licensed vaccines are available to LASV infections, and anti-LASV drug therapy is limited to an off-label use of ribavirin (Rib) that is only partially effective. The development of reverse genetics has provided investigators with a novel and powerful approach for the investigation of the molecular, cell biology, and pathogenesis of LASV. The use of cell-based LASV minigenome (MG) systems has allowed examining the cis- and trans-acting factors involved in genome replication and gene transcription and the identification of novel drugable LASV targets. Likewise, it is now feasible to rescue infectious recombinant (r)LASV entirely from cloned cDNAs containing predetermined mutations in their genomes to investigate virus-host interactions and mechanisms of pathogenesis, as well as to facilitate screens to identify antiviral drugs against LASV and the implementation of novel strategies to develop live-attenuated vaccines (LAV). In this chapter we will summarize the stateof- the-art experimental procedures for implementation of LASV reverse genetics. In addition, we will briefly discuss some significant translational research developments that have been made possible upon the development of LASV reverse genetics.

KW - Lassa virus minigenome assays

KW - Lassa virus rescue systems

KW - Lassa virus reverse genetics

KW - Recombinant Lassa virus

UR - http://www.scopus.com/inward/record.url?scp=85019556018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019556018&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-6964-7_13

DO - 10.1007/978-1-4939-6964-7_13

M3 - Chapter

C2 - 28508222

AN - SCOPUS:85019556018

VL - 1602

T3 - Methods in Molecular Biology

SP - 185

EP - 204

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -